Compare · NVO vs ZBIO
NVO vs ZBIO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zenas BioPharma Inc. (ZBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZBIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 162.0x ZBIO ($1.16B).
- Over the past year, NVO is down 46.8% and ZBIO is up 54.9% - ZBIO leads by 101.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for ZBIO).
- NVO has more recent analyst coverage (25 ratings vs 9 for ZBIO).
- Company
- Novo Nordisk A/S
- Zenas BioPharma Inc.
- Price
- $42.19+2.89%
- $18.50+4.49%
- Market cap
- $188.38B
- $1.16B
- 1M return
- -8.44%
- -5.76%
- 1Y return
- -46.83%
- +54.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest ZBIO
- Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
- Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
- Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
- Chief Executive Officer Moulder Leon O Jr bought $1,012,800 worth of shares (60,000 units at $16.88) (SEC Form 4)
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
- SEC Form 10-Q filed by Zenas BioPharma Inc.
- Zenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13D filed by Zenas BioPharma Inc.